Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 7:19 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1753–1776 of 79,327 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: 2 Clear all

Conditions: Obesity
Interventions: Freeze-dried whole-grape powder; Dietary Supplement
Lead sponsor: Texas Woman's University; Other
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Denton, Texas

Conditions: Smoking Cessation
Interventions: MI + CBST; Behavioral
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 16 Years to 20 Years
Enrollment: 2,151 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2015
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Irritable Bowel Syndrome
Interventions: Food Elimination Diet; Other
Lead sponsor: Biomerica; Industry
Eligibility: 21 Years and older
Enrollment: 556 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 8
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Wauconda, Illinois + 4 more

Conditions: Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions: Cyclophosphamide, Daratumumab, Dexamethasone, Ixazomib Citrate, Laboratory Biomarker Analysis; Drug · Biological · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2025
U.S. locations: 3
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota

Conditions: Rotator Cuff Tear, Fatty Atrophy
Interventions: Superiority of augmented repairs, Fat degeneration of supraspinatus muscle; Biological
Lead sponsor: Applied Biologics, LLC; Industry
Eligibility: Not listed
Enrollment: 260 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Obesity, Weight Loss
Interventions: Component 1: Calorie Goal Attainment, Component 2: Diet Quality, Component 3: Physical Activity Goal Attainment, Component 4: Goal Setting; Behavioral
Lead sponsor: University of Florida; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Major Depressive Disorder
Interventions: Interactive voice messaging or Interactive voice messaging + psycho ed materials; Behavioral
Lead sponsor: Kaiser Permanente; Other
Eligibility: 21 Years to 75 Years
Enrollment: 6,058 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Gallbladder Adenocarcinoma
Interventions: HIPEC; Drug
Lead sponsor: West Virginia University; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Gastroparesis, Diabetes Mellitus
Interventions: Placebo, Relamorelin; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 336 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 113
States / cities: Birmingham, Alabama • Dothan, Alabama • Huntsville, Alabama + 95 more

Conditions: Li-Fraumeni Syndrome
Interventions: Metformin; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Type 2 Diabetes
Interventions: icovamenib 100 mg, Placebo; Drug
Lead sponsor: Biomea Fusion Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 20
States / cities: Birmingham, Alabama • Canoga Park, California • Long Beach, California + 17 more

Conditions: Hypertension
Interventions: Revision of congregate meal menus and recipes to align with parameters of DASH eating plan, On-site blood pressure monitoring, Home self blood pressure monitoring, Medical adherence education, Nutrition Education; Behavioral
Lead sponsor: Rockefeller University; Other
Eligibility: 60 Years to 105 Years
Enrollment: 94 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Focus: Effects of Nicotine and Alcohol on Brain Circuits
Interventions: Nicotine + Alcohol, Placebo Nicotine + Alcohol, Nicotine + Placebo Alcohol; Drug
Lead sponsor: Mclean Hospital; Other
Eligibility: 21 Years to 40 Years · Male only
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Belmont, Massachusetts

Conditions: Weight, Body
Interventions: Risperidone, Aripiprazole; Drug
Lead sponsor: Duke University; Other
Eligibility: 3 Years to 18 Years
Enrollment: 509 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 37
States / cities: Dothan, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 32 more

Conditions: Cancer, Depression
Interventions: Technology-Enabled Tailored Referral; Behavioral
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Vocal Fold Nodules, Muscle Tension Dysphonia
Interventions: Ambulatory voice biofeedback; Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Waldenstrom's Macroglobulinemia
Interventions: CC-5103 (lenalidomide), Rituximab; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years to 80 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Substance Use Disorders, Parenting
Interventions: PURPOSE; Behavioral
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 21 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Diabetes Mellitus, Type 2
Interventions: U-500R; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Malignant Mesothelioma, Non-Small Cell Lung Carcinoma, Pleural Disorder
Interventions: Light Dosimetry for Intranoperative Therapy, Photodynamic Therapy, Porfimer Sodium; Device · Procedure · Drug
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Prostate Cancer
Interventions: filgrastim, monoclonal antibody m170, cyclosporine, paclitaxel, peripheral blood stem cell transplantation, indium In 111 monoclonal antibody m170, yttrium Y 90 monoclonal antibody m170; Biological · Drug · Procedure + 1 more
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2001
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Healthy Participants, Hepatic Impairment
Interventions: Casdatifan; Drug
Lead sponsor: Arcus Biosciences, Inc.; Industry
Eligibility: 18 Years to 84 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Stiffness; Spine
Interventions: Static Cupping, Dynamic Cupping, Stretching; Other
Lead sponsor: University of South Carolina; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Columbia, South Carolina

Conditions: Glioblastoma
Interventions: bosutinib; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 2
States / cities: Boston, Massachusetts

Search by objective public record fields.

Effect of Whole-grape Powder on Body Composition, Fat and Bone Serum Biomarkers in Postmenopausal Women

Hutchinson Study of High School Smoking

Endpoint Determination Study Protocol

Ixazomib Citrate in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib

Efficacy of an Amniotic Fluid Derived Allograft, (FlōGraft®) in Rotator Cuff Repairs: A Prospective Study

Optimizing Self-Monitoring Feedback for the Treatment of Obesity

Antidepressant Adherence Via AD_IVR

Safety and Feasibility of HIPEC for High-Risk Gallbladder Adenocarcinoma

A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis 01

A Pilot Study of Metformin in Patients With a Diagnosis of Li-Fraumeni Syndrome

Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Mellitus Who Are Not Achieving Glycemic Targets While Using GLP-1-Based Therapy

DASH Diet Intervention at Senior Centers

Neural Mechanisms Underlying Nicotine and Alcohol Combinations

Long-term Antipsychotic Pediatric Safety Trial

Feasibility of a Technology-Based Intervention for Depression Referral Uptake in Cancer Survivors

Preliminary Study 2 to Test the Effects of Ambulatory Voice Biofeedback

CC-5013 (Lenalidomide) and Rituximab in Waldenstrom's Macroglobulinemia

PURPOSE: A Social Media Intervention for Parent Support

A Study of U-500 Insulin (LY041001) in Participants With Type 2 Diabetes

Light Dosimetry for Photodynamic Therapy With Porfimer Sodium in Treating Participants With Malignant Mesothelioma or Non-Small Cell Lung Cancer With Pleural Disease Undergoing Surgery

Monoclonal Antibody Therapy Plus Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy

Comparative PK Assessment Study of Casdatifan in Moderate Hepatically Impaired Participants Versus Matched Participants With Normal Hepatic Function

The Effects of Stretching Versus Static and Dynamic Cupping on Lumbar Range of Motion

Bosutinib in Adult Patients With Recurrent Glioblastoma